These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 5520376)

  • 21. Kinetics of norepinephrine metabolism in the rat heart in vivo.
    Volicer L
    Biochem Pharmacol; 1974 Feb; 23(3):697-703. PubMed ID: 4822750
    [No Abstract]   [Full Text] [Related]  

  • 22. Aspects of the biogenic amine-depleting activity of ethyl 3-acetamido-4H-pyrrolo-[3,4-c]isoxazole-5(6H)-carboxylate in the rat.
    Lippmann W; Wishnick M
    Br J Pharmacol Chemother; 1968 Jun; 33(2):257-65. PubMed ID: 5664146
    [No Abstract]   [Full Text] [Related]  

  • 23. Pre- and postsynaptic origin of the norepinephrine metabolites formed during transmitter release elicited by nerve stimulation.
    Langer SZ; Stefano FJ; Enero MA
    J Pharmacol Exp Ther; 1972 Oct; 183(1):90-102. PubMed ID: 4342928
    [No Abstract]   [Full Text] [Related]  

  • 24. On the physiological disposition and possible mechanism of the antihypertensive action of debrisoquin.
    Medina MA; Giachetti A; Shore PA
    Biochem Pharmacol; 1969 Apr; 18(4):891-901. PubMed ID: 5788526
    [No Abstract]   [Full Text] [Related]  

  • 25. In vivo inhibition of dopamine beta-hydroxylase by 1-phenyl-3-(2-thiazolyl)-2-thiourea (U-14,624).
    Johnson GA; Boukma SJ; Kim EG
    J Pharmacol Exp Ther; 1970 Jan; 171(1):80-7. PubMed ID: 5410940
    [No Abstract]   [Full Text] [Related]  

  • 26. Debrisoquine, guanethidine, propranolol and human sleep.
    Dunleavy DL; MacLean AW; Oswald I
    Psychopharmacologia; 1971; 21(2):101-10. PubMed ID: 4328215
    [No Abstract]   [Full Text] [Related]  

  • 27. The uptake and disposition of dl-norepinephrine in perfused rat lung.
    Hughes J; Gillis CN; Bloom FE
    J Pharmacol Exp Ther; 1969 Oct; 169(2):237-48. PubMed ID: 5824606
    [No Abstract]   [Full Text] [Related]  

  • 28. The use of intravenous tyramine and the cold pressor test to help elucidate a possible mechanism of action of a new isoquinoline compound shown to have antihypertensive properties in humans.
    Pocelinko R; Taylor WJ
    Int Z Klin Pharmakol Ther Toxikol; 1969 Jan; 2(1):13-9. PubMed ID: 4896482
    [No Abstract]   [Full Text] [Related]  

  • 29. A comparison of 6,7-dihydroxytetrahydroisoquinoline, salsolinol and tetrahydropapaveroline as inhibitors of monoamine oxidase within the adrenergic nerve plexus of the isolated mouse atrium.
    Katz S; Cohen G
    Res Commun Chem Pathol Pharmacol; 1976 Feb; 13(2):217-24. PubMed ID: 1257609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of uptake2 in the extraneuronal metabolism of catecholamines in the isolated rat heart.
    Lightman SL; Iversen LL
    Br J Pharmacol; 1969 Nov; 37(3):638-49. PubMed ID: 5348467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New antihypertensive drugs. II. Debrisoquin or Declinax].
    Amery A; Deruyttere M; Fagard R; Koninckx P
    Acta Clin Belg; 1970; 25(5):317-34. PubMed ID: 5513889
    [No Abstract]   [Full Text] [Related]  

  • 32. Neuronal and extraneuronal uptake and efflux of catecholamines in the isolated rabbit heart.
    Lindmar R; Löffelholz K
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 284(1):63-92. PubMed ID: 4279349
    [No Abstract]   [Full Text] [Related]  

  • 33. The effect of bretylium on amine retention in rat heart.
    Krauss KR; Kopin IJ; Weise VK
    J Pharmacol Exp Ther; 1970 Apr; 172(2):282-8. PubMed ID: 4392531
    [No Abstract]   [Full Text] [Related]  

  • 34. Debrisoquin, a selective inhibitor of intraneuronal monoamine oxidase in man.
    Pettinger WA; Korn A; Spiegel H; Solomon HM; Pocelinko R; Abrams WB
    Clin Pharmacol Ther; 1969; 10(5):667-74. PubMed ID: 5808462
    [No Abstract]   [Full Text] [Related]  

  • 35. Antihypertensive and monoamine oxidase inhibitory activity of 3-amino-2-oxazolidinone (3AO) and its condensation product with 2-substituted-3-formyl-4-oxo-(4H) pyrido(1,2-a)pyrimidines.
    Kaul CL; Grewal RS
    Biochem Pharmacol; 1972 Feb; 21(3):303-16. PubMed ID: 5014489
    [No Abstract]   [Full Text] [Related]  

  • 36. [On the pharmacology of prenylamine].
    Grobecker H; Palm D; Holtz P
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1968; 260(5):379-99. PubMed ID: 4387688
    [No Abstract]   [Full Text] [Related]  

  • 37. Production of ( 3 H)catecholamines in the brain following the peripheal administration of 3 H-dopa during pre- and postnatal development.
    Kellogg C; Lundborg P
    Brain Res; 1972 Jan; 36(2):333-42. PubMed ID: 5061894
    [No Abstract]   [Full Text] [Related]  

  • 38. Antihypertensive and monoamine oxidase inhibitory activity of some derivatives of 3-formyl-4-oxo-4H-pyrido (1,2-a) pyrimidine.
    George T; Kaul CL; Grewal RS; Tahilramani R
    J Med Chem; 1971 Oct; 14(10):913-5. PubMed ID: 4398920
    [No Abstract]   [Full Text] [Related]  

  • 39. Studies on the mechanism of tolerance to nicotine-induced elevations of urinary catecholamines.
    Westfall TC; Brase DA
    Biochem Pharmacol; 1971 Jul; 20(7):1627-35. PubMed ID: 5163092
    [No Abstract]   [Full Text] [Related]  

  • 40. Some puzzling pharmacological effects of monoamine oxidase inhibitors.
    Knoll J; Magyar K
    Adv Biochem Psychopharmacol; 1972; 5():393-408. PubMed ID: 5066229
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.